MDS-specific comorbidity index is useful to identify myelodysplastic patients who can have better outcome with 5-azacitidine

Haematologica

Volumn 97, Issue 2, 2012, Pages

  Breccia, Massimo ^a   Salaroli, Adriano ^a   Loglisci, Giuseppina ^a   Finsinger, Paola ^a   Serrao, Alessandra ^a   Alimena, Giuliana ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Comorbidities; MDS; Risk stratification; WPSS

Indexed keywords

AZACITIDINE;

ADULT; AGED; CHROMOSOME ANALYSIS; CHRONIC LYMPHATIC LEUKEMIA; COMORBIDITY; DISEASE COURSE; FEMALE; HIGH RISK PATIENT; HUMAN; KARYOTYPE; LETTER; MAJOR CLINICAL STUDY; MALE; MONOSOMY 7; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; SURVIVAL RATE; VALIDITY;

FEMALE; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES;

EID: 84856459188     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.059808     Document Type: Letter

References (4)

1. Della Porta MG, Malcovati L, Strupp C, Ambaglio I, Kuendgen A, Zipperer E, et al. Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodys-plastic syndrome. Haematologica. 2011;96(3):441-9.
2. Breccia M, Federico V, Loglisci G, Salaroli A, Serrao A, Alimena G. Evaluation of overall survival according to MDS-specific comor-bidity index on a large series of myelodysplastic syndromes. Haematologica. 2011;96(10):e41-2.
3. Itzkynson R, Thepot S, Quesnel B, Dreyfus F, Beyne-Rauzy O, Turlure P, et al. Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood. 2011;117(2):403-11.
4. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006;108(2):419-25.